AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$BMRN

Biomarin Pharma earnings beat by $0.11, revenue topped estimates

Biomarin Pharma (BMRN) reported Q3 EPS of $0.23, beating estimates by $0.11, with revenue of $1.03B, slightly above expectations. The stock is down 6.54% over 3 months but up 8.68% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Nov 2, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMRN
Bullish
high confidence
Mentioned
$BMRN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMRNBullishHigh
01

Why it matters

The earnings surprise provides a fresh catalyst for short‑term trading, with potential upside if the market has not fully priced the beat.

02

Market read

Earnings beat is a primary driver for BMRN's near‑term price action and may influence biotech sector sentiment.

03

What to watch

Guidance outlook and pipeline updates were not disclosed, which could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Biomarin Pharma (NASDAQ:BMRN) released its third‑quarter earnings, showing a modest beat on both earnings per share and revenue.

Company-level read

Ticker impact

$BMRNBullishHigh confidence
Context

Biomarin Pharma reported Q3 EPS of $0.23, beating estimates by $0.11 and revenue of $1.03B versus $1.02B consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The surprise EPS and revenue beat provide fresh, material information that can move the share price in the near term.

Market effects

Sector

Positive earnings may lift other biotech peers.

Regional

Minimal regional effect beyond US biotech sector.

Global

Limited to investors tracking biotech earnings.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short-term profit taking.

Key entities

  • company
    Biomarin Pharma

    Biotech firm reporting Q3 earnings.

Read at source← All news

StoryBioMarin posts Q3 2026 revenue above $1 billion but trims full‑year outlook

Also covered by

5 outlets

Related articles

NOV 3
$BMRNHighAI 8/10

BioMarin reports Q3 revenue beat but cuts full-year outlook

BioMarin Pharmaceutical (BMRN) reported Q3 revenue of $1.025B, beating estimates. EPS matched expectations at $0.23. The company lowered full-year revenue guidance by $50M and fiscal 2026 earnings guidance to $2.80-$3.10 per share, citing delays in Voxzogo orders and business development impacts. Management expects faster cost synergies from the Amicus acquisition.

investing.com2 min
NOV 3
$BMRNHighAI 8/10

BioMarin (BMRN) Q3 2026 Earnings Call Transcript

BioMarin (BMRN) reported Q3 2026 revenue growth of 44% in metabolic conditions, driven by Galafold, Pombility, and Opfolda, which generated over $200M combined. VOXZOGO saw a 17% increase in treated patients. The company updated guidance, citing order timing and geopolitical headwinds, and highlighted pipeline advancements like BMN-450 for Fabry disease. Galafold revenue was $152M, up 10% YoY, while Pombility and Opfolda revenue was $49M, up 58% YoY.

finance.yahoo.com3 min
NOV 3
$BMRNMedAI 8/10

BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin (BMRN) reported Q3 earnings, with Voxzogo revenue up 12% YoY to $245M. The company lowered 2026 revenue guidance to $3.8B-$3.9B due to order timing and regional disruptions. Non-GAAP EPS guidance is $2.80-$3.10, including impacts from recent acquisitions. BioMarin also provided updates on its pipeline, including BMN 450 for Fabry disease and BMN 440 for hypophosphatasia.

finance.yahoo.com3 min
NOV 2
$BMRNMedAI 8/10

BioMarin: Q3 Earnings Snapshot

BioMarin Pharmaceutical Inc. reported a Q3 loss of $122.8 million, or 63 cents per share, but adjusted earnings of 23 cents per share beat expectations. Revenue of $1.02 billion missed forecasts. The company expects full-year earnings of $2.80 to $3.10 per share and revenue of $3.8 billion to $3.9 billion. Shares are down 3% YTD but up 7% over 12 months.

finance.yahoo.com2 min